Cargando…
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities. This is demonstrated by the increasing number o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178595/ https://www.ncbi.nlm.nih.gov/pubmed/37175436 http://dx.doi.org/10.3390/ijms24097728 |
_version_ | 1785040902862929920 |
---|---|
author | Rizzo, Carla Amata, Sara Pibiri, Ivana Pace, Andrea Buscemi, Silvestre Palumbo Piccionello, Antonio |
author_facet | Rizzo, Carla Amata, Sara Pibiri, Ivana Pace, Andrea Buscemi, Silvestre Palumbo Piccionello, Antonio |
author_sort | Rizzo, Carla |
collection | PubMed |
description | The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities. This is demonstrated by the increasing number of newly synthesized fluorinated heterocyclic compounds among the Food and Drug Administration FDA-approved drugs. In this review, the biological activity, as well as the synthetic aspects, of 33 recently FDA-approved fluorinated heterocyclic drugs from 2016 to 2022 are highlighted. |
format | Online Article Text |
id | pubmed-10178595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101785952023-05-13 FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022 Rizzo, Carla Amata, Sara Pibiri, Ivana Pace, Andrea Buscemi, Silvestre Palumbo Piccionello, Antonio Int J Mol Sci Review The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities. This is demonstrated by the increasing number of newly synthesized fluorinated heterocyclic compounds among the Food and Drug Administration FDA-approved drugs. In this review, the biological activity, as well as the synthetic aspects, of 33 recently FDA-approved fluorinated heterocyclic drugs from 2016 to 2022 are highlighted. MDPI 2023-04-23 /pmc/articles/PMC10178595/ /pubmed/37175436 http://dx.doi.org/10.3390/ijms24097728 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rizzo, Carla Amata, Sara Pibiri, Ivana Pace, Andrea Buscemi, Silvestre Palumbo Piccionello, Antonio FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022 |
title | FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022 |
title_full | FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022 |
title_fullStr | FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022 |
title_full_unstemmed | FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022 |
title_short | FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022 |
title_sort | fda-approved fluorinated heterocyclic drugs from 2016 to 2022 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178595/ https://www.ncbi.nlm.nih.gov/pubmed/37175436 http://dx.doi.org/10.3390/ijms24097728 |
work_keys_str_mv | AT rizzocarla fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022 AT amatasara fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022 AT pibiriivana fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022 AT paceandrea fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022 AT buscemisilvestre fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022 AT palumbopiccionelloantonio fdaapprovedfluorinatedheterocyclicdrugsfrom2016to2022 |